Pharming Group (PHAR) Stock Price, News & Analysis

Company Overview

Pharming Group N.V. is a global biopharmaceutical company headquartered in Leiden, the Netherlands. The company develops and commercializes medicines for rare diseases and conditions with significant unmet medical needs, using biotechnology and protein-replacement approaches.

Pharming’s commercial products include Ruconest (conestat alfa), a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, and Joenja (leniolisib), an oral therapy for activated phosphoinositide 3-kinase delta syndrome, a rare primary immunodeficiency disorder. The company also maintains a pipeline focused on additional rare and specialty diseases.

Founded in 1988, Pharming serves patients and healthcare providers in the United States, Europe and other international markets through its own commercial operations and regional partnerships. Its shares trade on Euronext Amsterdam and, through American depositary shares, on the Nasdaq under the symbol PHAR.

Key Stats

• Today's Range: $9.74 to $10.08
• 50-Day Range: $9.75 to $12.86
• 52-Week Range: $9.62 to $21.34
• Volume: 10,813 shs
• Average Volume: 36,577 shs
• Market Capitalization: $693.64 million
• P/E Ratio: 81.67
• Dividend Yield: N/A
• Price Target: $38.67
• Consensus Rating: Hold

Pharming Group Stock Analysis - MarketRank™

Pharming Group scored higher than 89% of companies evaluated by MarketBeat, and ranked 37th out of 885 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Hold

Consensus Rating

Pharming Group has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 2 sell ratings.

Upside Potential

Pharming Group has a consensus price target of $38.67, representing about 294.6% upside from its current price of $9.80.

Amount of Analyst Coverage

Pharming Group has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 22.73%

Earnings Growth

Earnings for Pharming Group are expected to grow by 22.73% in the coming year, from $0.22 to $0.27 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Pharming Group is 81.67, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.66.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pharming Group is 81.67, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.34.

Price to Book Value per Share Ratio

Pharming Group has a P/B Ratio of 2.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.03% of the float of Pharming Group has been sold short.

Short Interest Ratio / Days to Cover

Pharming Group has a short interest ratio ("days to cover") of 1.22, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Pharming Group has recently decreased by 16.65%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pharming Group does not currently pay a dividend.

Dividend Growth

Pharming Group does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.45

News Sentiment

Pharming Group has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Pharming Group this week, compared to 3 articles on an average week.

Search Interest

3 people have searched for PHAR on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Pharming Group insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.07% of the stock of Pharming Group is held by insiders.

Percentage Held by Institutions

0.03% of the stock of Pharming Group is held by institutions.

Company Calendar

• Last Earnings: 7/30/2026
• Today: 10/06/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:PHAR
• CIK: 1828316
• Web: www.pharming.com
• Phone: 31-71-524-7400
• Fax: N/A
• Employees: 407
• Year Founded: 1988

Price Target and Rating

• Average Price Target for Pharming Group: $38.67
• High Price Target: $41.00
• Low Price Target: $37.00
• Potential Upside/Downside: +294.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.12
• Trailing P/E Ratio: 81.67
• Forward P/E Ratio: 44.55
• P/E Growth: N/A
• Net Income: $2.85 million
• Net Margins: 2.51%
• Pretax Margin: 4.31%
• Return on Equity: 3.40%
• Return on Assets: 1.90%

Debt

• Debt-to-Equity Ratio: 0.34
• Current Ratio: 3.01
• Quick Ratio: 2.31

Sales & Book Value

• Annual Sales: $376.13 million
• Price / Sales: 1.84
• Cash Flow: $0.20 per share
• Price / Cash Flow: 48.62
• Book Value: $3.95 per share
• Price / Book: 2.48

Miscellaneous

• Outstanding Shares: 70,780,000
• Free Float: 69,313,000
• Market Cap: $693.64 million
• Optionable: Not Optionable
• Beta: -0.05